Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.

Gábor Lakatos(Unified Szent István and Szent László Hospital), G. Bodoky(Unified Szent István and Szent László Hospital), László Nehéz(Semmelweis University), Á Petrányi(Unified Szent István and Szent László Hospital), Péter Hegyi(Semmelweis University), Attila Szücs(Semmelweis University), László Harsányi(Semmelweis University)

Pathology & Oncology Research

January 6, 2017

10.1007/s12253-016-0176-0

Cited by 22

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

ESPEN Guidelines on Enteral Nutrition: Surgery including Organ Transplantation

|Clinical Nutrition|2006|1.1k

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

|The Lancet Oncology|2015|954

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

|The Lancet Oncology|2013|838

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

|Annals of Oncology|2014|603